FARE - Food Allergy Research & Education Logo

Hydrolysed Rice Formula Study

Study Purpose

This non-inferiority study aims to determine whether a hydrolysed rice protein formula is as effective as a cow's milk protein based extensively hydrolysed formula using a double-blind, randomised-controlled design over a 28-day intervention period followed by a 2-month follow-up period in infants 0-13 months of age presenting with symptoms/clinical history suggestive of cow's milk allergy. The primary outcome is growth, and secondary outcomes are gastrointestinal tolerance, and differences in intake, allergic symptoms, parental QOL, acceptability, dietary intake, and safety.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 0 Months - 13 Months
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Male or female.
  • - Aged 0-13 months.
  • - Presenting to primary or secondary care with symptoms/clinical history suggestive of CMA.
  • - Will receive at least 30% of energy requirements from the study formula.
  • - Written informed consent from parent/carer.

Exclusion Criteria:

  • - Severe CMA (including anaphylaxis) and/or requiring an AAF.
  • - Faltering growth (based on NICE guidelines36 - Appendix 1) - Previous allergy to any study product ingredients (including whey hydrolysate and/or rice) - Primary lactose intolerance.
  • - Food Protein-Induced Enterocolitis Syndrome (FPIES) - Exclusively breast fed.
  • - Severe concurrent or chronic disease or genetic syndrome that may impact growth or other outcomes.
  • - Severe hepatic or renal insufficiency.
  • - Premature infants (born <37 weeks) with a corrected age of <4 weeks.
  • - Requirement for any parenteral nutrition.
  • - Participation in other clinical intervention studies within 1 month of recruitment.
- Concern around the willingness/ability of the caregiver to comply with the study protocol and/or study requirements

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06288503
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

N/A
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Nutricia UK Ltd
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries United Kingdom
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Cow's Milk Protein Allergy
Arms & Interventions

Arms

Experimental: Intervention

Hydrolysed rice protein formula

Active Comparator: Control

Cow's milk based extensively hydrolysed formula

Interventions

Other: - Hydrolysed Rice Protein Formula

Infants randomised onto this arm will be taking the hydrolysed rice protein formula, with a minimum prescription of 30% of their energy requirements.

Other: - Cow's Milk Based Extensively Hydrolysed Formula

Infants randomised onto this arm will be taking the control product, with a minimum prescription of 30% of their energy requirements.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Gloucestershire Royal NHS Trust, Gloucester, Gloucestershire, United Kingdom

Status

Recruiting

Address

Gloucestershire Royal NHS Trust

Gloucester, Gloucestershire, GL1 3NN

Site Contact

Victoria Bittle

[email protected]

0300 422 5506

Bristol Royal Hospital for Children, Bristol, Somerset, United Kingdom

Status

Recruiting

Address

Bristol Royal Hospital for Children

Bristol, Somerset, BS16 1TA

Site Contact

Sarah Trace

[email protected]

0117 3428802

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.